GELESIS HOLDINGS, INC. (CPSR) - Dilution Analysis

8-K filing: Gelesis Holdings Inc. issued an Additional Note in the principal amount of $1.5 million to PureTech Health LLC. ($10.35M proceeds)

10-Q filing | 73.3M shares outstanding

8-K filing: Gelesis Holdings Inc. amended its Note and Warrant Purchase Agreement with the Initial Investor, extending the maturity date of the Notes to March 31, 2024, and the Note Issuers have issued to the Initial Investor $10.35 million aggregate principal amount of Notes, together with Warrants to purchase an aggregate of 259,129,542 shares of Common Stock. ($0.0M proceeds)

8-K filing: Gelesis Holdings, Inc. entered into a merger agreement with PureTech Health LLC, where Gelesis will merge into a subsidiary of PureTech. Parent provided $3.0 million of bridge financing to the Company pursuant to Parent's purchase, for a $3.0 million cash purchase price, of an Additional Note in the principal amount of $3.0 million. ($7.35M proceeds)

8-K filing: Gelesis Holdings, Inc. issued additional warrants to PureTech Health LLC to purchase up to 43,133,803 shares of Common Stock at an exercise price of $0.0142 for a cash purchase price of $350,000. ($7.35M proceeds)

10-Q filing | 73.3M shares outstanding

8-K filing: Gelesis Holdings, Inc. issued additional notes and warrants to PureTech Health LLC for $2.0 million, with warrants to purchase up to 192,307,692 shares of common stock at an exercise price of $0.0182. ($2.0M proceeds)

10-K filing | 70.3M shares outstanding

POS AM filing: This is a POS AM filing for Gelesis Holdings, Inc. relating to the resale of various securities including common stock, warrants, PIPE shares, backstop shares, founder shares, shares issued to Gelesis, Inc. holders, shares underlying warrants and rollover options, and earnout shares.

POS AM filing: This POS AM filing from Gelesis Holdings, Inc. relates to an equity line offering where the company may elect to sell up to $50,000,000 of common stock to a selling securityholder. The company intends to use the proceeds for general corporate purposes, including working capital.

8-K filing: Gelesis Holdings, Inc. entered into a Note and Warrant Purchase Agreement with PureTech Health LLC, issuing a $5.0 million convertible senior secured note and warrants to purchase 23,688,047 shares of common stock for a cash purchase price of $5.0 million.

10-Q filing | 73.0M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 35,891,461 shares of our Common Stock by B. Riley Principal Capital II, LLC pursuant to a common stock purchase agreement, dated as of August 11, 2022, we entered into with B. Riley Principal Capital II, which we refer to in this prospectus as the Purchase Agreement.

10-Q filing | 72.6M shares outstanding

8-K filing: Gelesis Holdings, Inc. entered into a Common Stock Purchase Agreement with B. Riley Principal Capital II, LLC, potentially allowing the Company to sell up to $50,000,000 of newly issued shares of common stock to B. Riley over a 24-month period, and issued 355,361 commitment shares to B. Riley upon execution of the agreement.

8-K filing: Gelesis issued a warrant to CMS for 400,000 shares of common stock at $0.01 per share, issued promissory notes totaling $25 million to CMS, PureTech and SSD2, potentially convertible into common stock with warrants, and amended the exercise price of One S.r.l. warrants. ($0.0M proceeds)

S-1/A filing: This S-1/A filing relates to the resale of common stock and warrants of Gelesis Holdings, Inc. by selling securityholders.

10-Q filing | 72.4M shares outstanding

S-1/A filing: This prospectus relates to the resale of shares of common stock, founder shares, shares of common stock issued in connection with the Business Combination, shares of Common Stock that may be issued upon exercise of the Private Placement Warrants, shares of Common Stock that may be issued upon exercise of the Public Warrants, shares of Common Stock that may be issued upon exercise of Rollover Warrants, shares of Common Stock issuable upon exercise of the Rollover Options, Earnout Shares and Warrants held by the Selling Securityholders.

10-K filing | 6.9M shares outstanding

S-1 filing: This prospectus relates to the resale of shares of common stock and warrants by selling securityholders.

8-K filing: CPSR (now Gelesis Holdings, Inc.) completed unregistered sales of equity securities, including 9,000,000 shares of Class A Common Stock to PIPE Investors at $10.00 per share for $90,000,000 in gross proceeds, and 744,217 Backstop Purchase Shares to Backstop Purchasers for $7,442,170, along with 1,983,750 Backstop Sponsor Shares. ($97.44M proceeds)

8-K filing: Capstar Special Purpose Acquisition Corp. (CPSR) is undergoing a business combination with Gelesis, involving PIPE Financing and a Backstop Agreement to ensure a minimum cash condition of $105 million for the merger. ($46.6M proceeds)

8-K filing: Capstar Special Purpose Acquisition Corp. entered into a Backstop Agreement with PureTech Health LLC and SSD2, LLC, where the Purchasers agreed to purchase up to 1,500,000 Capstar Class A Shares at $10.00 per share, resulting in proceeds of up to $15.0 million, and the Company will issue to the Purchasers 1,983,750 Capstar Class A Shares. ($15.0M proceeds)

10-Q filing | 6.9M shares outstanding

8-K filing: Capstar Special Purpose Acquisition Corp. amended its Business Combination Agreement with Gelesis, adjusting the equity valuation, increasing the number of Earn Out Shares, providing for additional Capstar Class A Shares to Company Stockholders, and extending the Termination Date.

10-Q filing | 6.9M shares outstanding

8-K filing: Capstar Special Purpose Acquisition Corp. (CPSR) has entered into Subscription Agreements with PIPE Investors for the private placement of up to 10,000,000 shares of CPSR Class A Common Stock at $10.00 per share, resulting in gross proceeds of up to $100 million, contingent upon the closing of a business combination with Gelesis, Inc. ($100.0M proceeds)

10-Q filing | 27.6M shares outstanding

10-K filing | 27.6M shares outstanding

10-Q filing | 27.6M shares outstanding

10-Q filing | 27.6M shares outstanding

8-K filing: Capstar Special Purpose Acquisition Corp. completed its initial public offering of 27,600,000 units at $10.00 per Unit, generating gross proceeds of $276,000,000, and simultaneously completed a private placement of 7,520,000 warrants at $1.00 per warrant, generating total gross proceeds of $7,520,000. ($283.52M proceeds)

8-K filing: Capstar Special Purpose Acquisition Corp. consummated its IPO of 27,600,000 units at $10.00 per unit, generating gross proceeds of $276,000,000, and simultaneously consummated a private placement of 7,520,000 warrants to the Sponsor at $1.00 per warrant, generating gross proceeds of $7,520,000. ($283.52M proceeds)

S-1/A filing: Capstar Special Purpose Acquisition Corp. is offering 20,000,000 units in an initial public offering, with each unit consisting of one share of Class A common stock and one-half of one redeemable warrant, and our sponsor has agreed to purchase an aggregate of 6,000,000 warrants in a private placement that will close simultaneously with the closing of this offering.

S-1 filing: Capstar Special Purpose Acquisition Corp. is offering 20,000,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-half of one redeemable warrant, in an initial public offering.